| Name | Title | Contact Details |
|---|
Hepalink was established in 1998 and restructured in 2007 to be a limited liability company.
Medly Pharmacy is a full-service, digital pharmacy that delivers your prescription medication to you for free, same day, anywhere in New York City and New Jersey. We created a digital experience that makes managing your prescription simple, efficient, and smart for patients and providers.
Maat Nutritionals is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leveraging the power of claims data from more than 200 million Americans, Blue Health Intelligence® (BHI®) delivers insights that empower healthcare organizations to improve patient care, reduce costs, and optimize performance. With the largest, most up-to-date, and uniform data set in healthcare, BHI provides an accurate representation of the health profile of commercially insured Americans. BHI is a trade name of Health Intelligence Company, LLC, an independent licensee of the Blue Cross Blue Shield Association.
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.